CD38 and plasma cell myeloma: Therefore, we attempted additional experiments to confirm whether venetoclax could enhance CDC by daratumumab using two CD38-positive myeloma cell lines (KMS12PE [10] and KMS27 [11]), which were used in this study and had revealed daratumumab mediated ADCC.